FDA to Review Extending Uses for AstraZeneca-Controlled Drug
06 Gennaio 2020 - 1:51PM
Dow Jones News
By Micah Maidenberg
AstraZeneca PLC (AZN) said regulators in the U.S. will consider
extending uses of its drug Farxiga.
The company said Monday the U.S. Food and Drug Administration
accepted a supplemental new-drug application for Farxiga, agreeing
to conduct a priority review of the therapy.
Regulators, in the new review, will consider the drug's use to
treat patients facing the risk of cardiovascular death or the
worsening of heart failure in some patients.
Adults with type two diabetes treat that disease with Farxiga,
according to a website for the drug.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
January 06, 2020 07:36 ET (12:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024